DK3450553T3 - Mrna-terapi til behandling af øjensygdomme - Google Patents
Mrna-terapi til behandling af øjensygdomme Download PDFInfo
- Publication number
- DK3450553T3 DK3450553T3 DK18201321.9T DK18201321T DK3450553T3 DK 3450553 T3 DK3450553 T3 DK 3450553T3 DK 18201321 T DK18201321 T DK 18201321T DK 3450553 T3 DK3450553 T3 DK 3450553T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- eye diseases
- mrna therapy
- mrna
- therapy
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969483P | 2014-03-24 | 2014-03-24 | |
| EP15767977.0A EP3122878B1 (en) | 2014-03-24 | 2015-03-19 | Mrna therapy for the treatment of ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3450553T3 true DK3450553T3 (da) | 2020-02-10 |
Family
ID=54196241
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15767977.0T DK3122878T3 (da) | 2014-03-24 | 2015-03-19 | Mrna-terapi til behandling af øjensygdomme |
| DK18201321.9T DK3450553T3 (da) | 2014-03-24 | 2015-03-19 | Mrna-terapi til behandling af øjensygdomme |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15767977.0T DK3122878T3 (da) | 2014-03-24 | 2015-03-19 | Mrna-terapi til behandling af øjensygdomme |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170143848A1 (da) |
| EP (3) | EP3122878B1 (da) |
| CY (1) | CY1121348T1 (da) |
| DK (2) | DK3122878T3 (da) |
| ES (2) | ES2707969T3 (da) |
| HR (1) | HRP20190117T1 (da) |
| HU (1) | HUE041940T2 (da) |
| LT (1) | LT3122878T (da) |
| ME (1) | ME03314B (da) |
| PL (1) | PL3122878T3 (da) |
| PT (1) | PT3122878T (da) |
| RS (1) | RS58337B1 (da) |
| SI (1) | SI3122878T1 (da) |
| SM (1) | SMT201900176T1 (da) |
| TR (1) | TR201900649T4 (da) |
| WO (1) | WO2015148247A1 (da) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| EP4074693A1 (en) | 2011-06-08 | 2022-10-19 | Translate Bio, Inc. | Cleavable lipids |
| CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and uses thereof |
| MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| US20210206818A1 (en) | 2016-01-22 | 2021-07-08 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| EP3442590A2 (en) | 2016-04-13 | 2019-02-20 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| EP4582089A2 (en) * | 2016-11-23 | 2025-07-09 | Mayo Foundation for Medical Education and Research | Particle-mediated delivery of biologics |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| IL268857B2 (en) | 2017-02-27 | 2024-09-01 | Translate Bio Inc | Methods for purification of messenger rna |
| IL268856B2 (en) | 2017-02-27 | 2024-09-01 | Translate Bio Inc | Methods for purification of messenger rna |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| GB2575930A (en) | 2017-03-23 | 2020-01-29 | Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| WO2018213731A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| US20190300856A1 (en) * | 2017-08-16 | 2019-10-03 | Georgia Tech Research Corporation | Messenger RNA based expression of opsins and reporter proteins for electrophysiologic characterization of in vitro neurons and cardiomyocytes |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| AU2018352592B2 (en) | 2017-10-16 | 2025-03-27 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
| JP2021515808A (ja) * | 2018-03-01 | 2021-06-24 | ジョージア テック リサーチ コーポレイション | ｍＲＮＡに基づく細胞表現型の調節および検出のための方法および組成物 |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| CN116059404A (zh) | 2018-06-11 | 2023-05-05 | 加利福尼亚大学董事会 | 用以治疗眼睛疾病的脱甲基化 |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| WO2020041793A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| EP3846857A4 (en) | 2018-09-04 | 2022-10-12 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS |
| JP7425066B2 (ja) | 2018-09-04 | 2024-01-30 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 核酸を臓器特異的送達するための組成物および方法 |
| WO2020061284A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| PL3864163T3 (pl) | 2018-10-09 | 2024-05-20 | The University Of British Columbia | Kompozycje i układy zawierające pęcherzyki zdolne do transfekcji wolne od rozpuszczalników organicznych i detergentów oraz związane z nimi sposoby postępowania |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| EP3877538A1 (en) | 2018-11-08 | 2021-09-15 | Translate Bio, Inc. | Methods and compositions for messenger rna purification |
| EP3876914A2 (en) * | 2018-11-09 | 2021-09-15 | Translate Bio, Inc. | Messenger rna therapy for treatment of ocular diseases |
| JP2022516356A (ja) * | 2019-01-07 | 2022-02-25 | トランスレイト バイオ， インコーポレイテッド | 原発性線毛機能不全症の治療のための組成物および方法 |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3920950A1 (en) * | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| JP7669281B2 (ja) | 2019-03-19 | 2025-04-28 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US11771652B2 (en) | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4314046A4 (en) * | 2021-04-01 | 2025-03-19 | ModernaTX, Inc. | Mucosal expression of antibody structures and isotypes by mRNA |
| CA3230031A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| IL312452A (en) | 2021-11-01 | 2024-06-01 | Tome Biosciences Inc | A transformant has a single structure for the simultaneous transfer of a gene editing mechanism and a nucleic acid cargo |
| US20250057980A1 (en) | 2021-12-22 | 2025-02-20 | Tome Biosciences, Inc. | Co-Delivery of a Gene Editor Construct and a Donor Template |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
| WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
| WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| AU2023274371A1 (en) | 2022-05-25 | 2024-10-31 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
| DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
| WO2024138194A1 (en) | 2022-12-22 | 2024-06-27 | Tome Biosciences, Inc. | Platforms, compositions, and methods for in vivo programmable gene insertion |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024234006A1 (en) | 2023-05-11 | 2024-11-14 | Tome Biosciences, Inc. | Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs) |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2025050069A1 (en) | 2023-09-01 | 2025-03-06 | Tome Biosciences, Inc. | Programmable gene insertion using engineered integration enzymes |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| EP1021549A2 (en) * | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| WO2005007810A2 (en) * | 2003-06-16 | 2005-01-27 | Grinstaff Mark W | Functional synthetic molecules and macromolecules for gene delivery |
| AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| BRPI0610499A2 (pt) * | 2005-04-12 | 2010-06-22 | Intradigm Corp | moléculas de ácido nucléico , composições e usos das referidas moléculas |
| US8039445B2 (en) | 2005-04-18 | 2011-10-18 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
| CA2659301A1 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| JP5777519B2 (ja) | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| US9019345B2 (en) | 2010-07-02 | 2015-04-28 | Intuitive Surgical Operations, Inc. | Imaging mode blooming suppression |
| US8853377B2 (en) * | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| ES2385080B1 (es) | 2010-12-21 | 2013-05-10 | Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea | Nanopartículas lipídicas para el tratamiento de enfermedades oculares. |
| EP4074693A1 (en) | 2011-06-08 | 2022-10-19 | Translate Bio, Inc. | Cleavable lipids |
| EP3586861B1 (en) | 2011-06-08 | 2022-02-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| PE20181541A1 (es) * | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| RS58562B1 (sr) * | 2011-11-04 | 2019-05-31 | Nitto Denko Corp | Postupak za sterilnu proizvodnju čestica lipid-nukleinska kiselina |
| EP2791160B1 (en) * | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
| EP2607375A1 (en) | 2011-12-21 | 2013-06-26 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Variants of yeast NDI1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction. |
| US9877919B2 (en) * | 2012-03-29 | 2018-01-30 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
| AU2013237873B2 (en) * | 2012-03-29 | 2017-12-14 | Translate Bio, Inc. | Ionizable cationic lipids |
| CA2868393A1 (en) * | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| DK2970456T3 (da) * | 2013-03-14 | 2021-07-05 | Translate Bio Inc | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer |
| JP6525435B2 (ja) * | 2013-10-22 | 2019-06-12 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａの送達のための脂質製剤 |
| EA034103B1 (ru) * | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| EP3060303B1 (en) * | 2013-10-22 | 2018-11-14 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
-
2015
- 2015-03-19 DK DK15767977.0T patent/DK3122878T3/da active
- 2015-03-19 ES ES15767977T patent/ES2707969T3/es active Active
- 2015-03-19 ME MEP-2019-13A patent/ME03314B/me unknown
- 2015-03-19 HR HRP20190117TT patent/HRP20190117T1/hr unknown
- 2015-03-19 EP EP15767977.0A patent/EP3122878B1/en active Active
- 2015-03-19 SM SM20190176T patent/SMT201900176T1/it unknown
- 2015-03-19 TR TR2019/00649T patent/TR201900649T4/tr unknown
- 2015-03-19 EP EP19218561.9A patent/EP3699274A1/en active Pending
- 2015-03-19 WO PCT/US2015/021403 patent/WO2015148247A1/en active Application Filing
- 2015-03-19 ES ES18201321T patent/ES2774552T3/es active Active
- 2015-03-19 PT PT15767977T patent/PT3122878T/pt unknown
- 2015-03-19 PL PL15767977T patent/PL3122878T3/pl unknown
- 2015-03-19 HU HUE15767977A patent/HUE041940T2/hu unknown
- 2015-03-19 SI SI201530559T patent/SI3122878T1/sl unknown
- 2015-03-19 DK DK18201321.9T patent/DK3450553T3/da active
- 2015-03-19 RS RS20190099A patent/RS58337B1/sr unknown
- 2015-03-19 EP EP18201321.9A patent/EP3450553B1/en active Active
- 2015-03-19 LT LTEP15767977.0T patent/LT3122878T/lt unknown
- 2015-03-19 US US15/128,303 patent/US20170143848A1/en not_active Abandoned
-
2019
- 2019-01-22 CY CY20191100085T patent/CY1121348T1/el unknown
-
2022
- 2022-02-03 US US17/592,335 patent/US20220354968A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI3122878T1 (sl) | 2019-05-31 |
| CY1121348T1 (el) | 2020-05-29 |
| ME03314B (me) | 2019-10-20 |
| RS58337B1 (sr) | 2019-03-29 |
| PL3122878T3 (pl) | 2019-06-28 |
| US20220354968A1 (en) | 2022-11-10 |
| EP3699274A1 (en) | 2020-08-26 |
| EP3450553B1 (en) | 2019-12-25 |
| TR201900649T4 (tr) | 2019-02-21 |
| PT3122878T (pt) | 2019-02-01 |
| HUE041940T2 (hu) | 2019-06-28 |
| ES2707969T3 (es) | 2019-04-08 |
| EP3122878B1 (en) | 2018-10-24 |
| HRP20190117T1 (hr) | 2019-04-19 |
| EP3122878A1 (en) | 2017-02-01 |
| EP3450553A1 (en) | 2019-03-06 |
| ES2774552T3 (es) | 2020-07-21 |
| DK3122878T3 (da) | 2019-02-04 |
| EP3122878A4 (en) | 2017-08-30 |
| SMT201900176T1 (it) | 2019-05-10 |
| LT3122878T (lt) | 2019-02-11 |
| US20170143848A1 (en) | 2017-05-25 |
| WO2015148247A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3171928T3 (da) | Stimulationsmønstre til behandling af tørt øje | |
| EP3875139C0 (en) | TREATMENT OF VENOUS DISEASES | |
| DK3777855T3 (da) | Fremgangsmåder til behandling af fibrotiske sygdomme | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| IL257764B (en) | Methods for treatment of diseases | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme | |
| LT3119384T (lt) | Intrahepatinių cholestazinių ligų gydymas | |
| DK3237621T5 (da) | Varianter af human alpha-galactosidase | |
| DK3848028T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3448388T3 (da) | Dipeptidyl-peptidase-4-inhibitorer til topikal øjenbehandling af retinale neurodegenerative sygdomme | |
| IL253847A0 (en) | Methods of treating diseases | |
| DK3377061T3 (da) | Mirabegron til behandling af nethindesygdomme | |
| DK3182980T3 (da) | Behandling af glykosyleringsmangelsygdomme | |
| HUE063820T2 (hu) | Módszerek kardiovaszkuláris betegségek kezelésére |